CD4 and inflammatory bowel disease: In a separate study, a microfluidic multi‐organ model containing gut, liver, and circulating Treg and Th17 cell components was used to model the contributions of microbiome and liver metabolism to IBD.[55] This work revealed that microbiome‐derived short‐chain fatty acids can influence IBD severity based on the involvement of effector CD4 T cells.